Press Release
January 4, 2024

Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases

The Life Sciences team advised Flagship Pioneering in Novo Nordisk’s separate research collaborations with Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity, Inc.  

The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. 

The Cellarity collaboration aims to unravel novel biological drivers of metabolic dysfunction-associated steatohepatitis and will leverage Cellarity’s platform to develop a small molecule therapy against this disease. 

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. 

The Goodwin team was led by Christopher Denn, Ed Amer, Nancy Urizar, Brittany Morreale, David Sackstein, Frank Qin, Kat Stavrianidis and Libby Sousa, with invaluable assistance from Kingsley Taft, Daniel Karelitz, Erika Pey, Susan Lee, Sarah Wicks, Matt Wetzel, Robert Frederickson, Robert Carroll, Paul Jin and Simone Waterbury.   

These are the first two programs signed under the previously announced framework collaboration between Flagship Pioneering and Novo Nordisk to leverage Flagship’s bioplatform companies to develop novel treatment approaches for cardiometabolic diseases.  

The Goodwin team who advised on the framework collaboration was led by Kingsley Taft, Nancy Urizar and Dan Karelitz. 

For more details, read the press release and article in Endpoints News and Fierce Biotech